762 related articles for article (PubMed ID: 26015857)
21. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
Newby LK
Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
[TBL] [Abstract][Full Text] [Related]
22. Pathological Q waves in myocardial infarction in patients treated by primary PCI.
Delewi R; Ijff G; van de Hoef TP; Hirsch A; Robbers LF; Nijveldt R; van der Laan AM; van der Vleuten PA; Lucas C; Tijssen JG; van Rossum AC; Zijlstra F; Piek JJ
JACC Cardiovasc Imaging; 2013 Mar; 6(3):324-31. PubMed ID: 23433932
[TBL] [Abstract][Full Text] [Related]
23. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
24. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
25. Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention.
Okmen E; Sanli A; Uyarel H; Dayi S; Tartan Z; Cam N
Angiology; 2006; 57(3):273-81. PubMed ID: 16703187
[TBL] [Abstract][Full Text] [Related]
26. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.
Meyer GP; Wollert KC; Lotz J; Steffens J; Lippolt P; Fichtner S; Hecker H; Schaefer A; Arseniev L; Hertenstein B; Ganser A; Drexler H
Circulation; 2006 Mar; 113(10):1287-94. PubMed ID: 16520413
[TBL] [Abstract][Full Text] [Related]
27. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
28. The clinical approach to diagnosing peri-procedural myocardial infarction after percutaneous coronary interventions according to the fourth universal definition of myocardial infarction - from the study group on biomarkers of the European Society of Cardiology (ESC) Association for Acute CardioVascular Care (ACVC).
Mair J; Jaffe A; Lindahl B; Mills N; Möckel M; Cullen L; Giannitsis E; Hammarsten O; Huber K; Krychtiuk K; Mueller C; Thygesen K
Biomarkers; 2022 Jul; 27(5):407-417. PubMed ID: 35603440
[TBL] [Abstract][Full Text] [Related]
29. Effects of timing on intracoronary autologous bone marrow-derived cell transplantation in acute myocardial infarction: a meta-analysis of randomized controlled trials.
Xu JY; Liu D; Zhong Y; Huang RC
Stem Cell Res Ther; 2017 Oct; 8(1):231. PubMed ID: 29037256
[TBL] [Abstract][Full Text] [Related]
30. A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial†.
Choudry F; Hamshere S; Saunders N; Veerapen J; Bavnbek K; Knight C; Pellerin D; Locca D; Westwood M; Rakhit R; Crake T; Kastrup J; Parmar M; Agrawal S; Jones D; Martin J; Mathur A
Eur Heart J; 2016 Jan; 37(3):256-63. PubMed ID: 26405233
[TBL] [Abstract][Full Text] [Related]
31. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy.
Dill T; Schächinger V; Rolf A; Möllmann S; Thiele H; Tillmanns H; Assmus B; Dimmeler S; Zeiher AM; Hamm C
Am Heart J; 2009 Mar; 157(3):541-7. PubMed ID: 19249426
[TBL] [Abstract][Full Text] [Related]
32. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.
Quintana M; Kahan T; Hjemdahl P
Am J Cardiovasc Drugs; 2004; 4(3):159-67. PubMed ID: 15134468
[TBL] [Abstract][Full Text] [Related]
34. Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data.
Silvain J; Zeitouni M; Paradies V; Zheng HL; Ndrepepa G; Cavallini C; Feldman DN; Sharma SK; Mehilli J; Gili S; Barbato E; Tarantini G; Ooi SY; von Birgelen C; Jaffe AS; Thygesen K; Montalescot G; Bulluck H; Hausenloy DJ
Eur Heart J; 2021 Jan; 42(4):323-334. PubMed ID: 33257958
[TBL] [Abstract][Full Text] [Related]
35. Incidence of high-risk acute coronary syndromes and eligibility for glycoprotein IIb/IIIa inhibitors among patients admitted for possible myocardial ischemia.
Kontos MC; Ornato JP; Schmidt KL; Tatum JL; Jesse RL
Am Heart J; 2002 Jan; 143(1):70-5. PubMed ID: 11773914
[TBL] [Abstract][Full Text] [Related]
36. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Bosch X; Marrugat J
Cochrane Database Syst Rev; 2001; (4):CD002130. PubMed ID: 11687143
[TBL] [Abstract][Full Text] [Related]
37. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
38. Electrocardiographic Q-wave "remodeling" in reperfused ST-segment elevation myocardial infarction: validation study with CMR.
Florian A; Slavich M; Masci PG; Janssens S; Bogaert J
JACC Cardiovasc Imaging; 2012 Oct; 5(10):1003-13. PubMed ID: 23058067
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of dynamic cardiac troponin I concentrations and C-reactive protein in the monitoring of myocardial infarction in patients with repeated myocardial infarction].
Plak M; Orliński L; Łobos M; Ciesielczyk M; Wlazeł RN; Paradowski MT
Pol Merkur Lekarski; 2010 Jun; 28(168):444-9. PubMed ID: 20642101
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
